Concentra Biosciences, LLC sent an unsolicited proposal to acquire Theseus Pharmaceuticals, Inc. (NasdaqGS:THRX) on November 24, 2023. As per consideration, Concentra Biosciences to acquire all outstanding shares of common stock of the Theseus Pharmaceuticals for $3.80 per share in cash, plus a contingent value right.
Theseus Pharmaceuticals, Inc.
Equities
THRX
US88369M1018
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
-2.70% | 102B | |
+2.26% | 96.09B | |
+2.13% | 22.28B | |
-17.24% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.83% | 16.09B | |
+6.07% | 13.83B | |
+32.42% | 11.97B |